Project Grant R01CA291826
Award Date
4/3/25
Completion Date
3/31/30
Dollars Obligated
$678K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $997,410 to Arizona State University to develop noninvasive MRI-based methods for detecting and differentiating between two high-grade glioma subtypes - the neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes. The researchers will leverage quantitative diffusion MRI to map the microstructural signatures of the NEU subtype's neurite-like microtubes, as...
This Project Grant award for $644,100 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to validate the use of MR Elastography (MRE) for early differentiation between tumor progression and pseudoprogression in glioblastoma (GBM) patients following chemoradiotherapy.
The project has two specific aims: 1) to validate distinctive MRE features of active tumor and treatment-related changes in a pre-operative cohort with tissue confirmation, and...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $627,061 in funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a research project focused on developing and testing a novel oncolytic herpes simplex virus (OHSV) immunotherapy for glioblastoma (GBM), a deadly form of brain cancer.
The key products and services to be delivered through this 5-year...
This Project Grant award of $419,133 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of the "AscitesPredictTM" technology at the Massachusetts Institute of Technology (MIT). The project aims to create an "ex vivo tumor biosensor" that can evaluate cell identities and therapeutic sensitivities from patient ascites fluid samples obtained during routine medical care. The technology utilizes...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $999,554 to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity lung cancer subtyping diagnostic test. The goal is to create a test that can accurately distinguish different lung cancer subtypes, enabling more effective treatment selection and improved patient outcomes. The award will fund the collection of clinical samples, enhancement of Orbit...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program supports research to develop an innovative approach to enrich cell-free DNA (cfDNA) for improved sensitivity of circulating nucleic acid-based diagnostics.
The $193,901 award, effective August 1, 2024 through May 31, 2028, will fund the development and testing of...